Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...

(MedPage Today) -- Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.
By week 72, participants on the dual GIP/GLP-1 receptor agonist tirzepatide lost 20.2% of body weight...